Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: MacroGenics, Inc.

Market Cap 252M 218M 200M 188M 352M 23.94B 357M 2.38B 924M 11.64B 945M 924M 40.32B P/E Ratio 2026 *
-5.9x
P/E Ratio 2027 * -2.59x
Enterprise Value 252M 218M 200M 188M 352M 23.94B 357M 2.38B 924M 11.64B 945M 924M 40.32B EV / Sales 2026 *
1.53x
EV / Sales 2027 * 2.67x
Free-Float
96.57%
Yield 2026 *
-
Yield 2027 * -
1 day-1.25%
1 week+1.28%
Current month-4.81%
1 month+14.78%
3 months+32.00%
6 months+182.86%
Current year+145.96%
1 week 3.81
Extreme 3.81
4.12
1 month 3.81
Extreme 3.81
4.64
Current year 1.58
Extreme 1.58
4.64
1 year 1.18
Extreme 1.185
4.64
3 years 0.99
Extreme 0.9897
21.88
5 years 0.99
Extreme 0.9897
29.16
10 years 0.99
Extreme 0.9897
36.48
Manager TitleAgeSince
Chief Executive Officer 53 12/08/2025
Director of Finance/CFO 59 30/04/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 31/08/2001
Director/Board Member 53 12/08/2025
Director/Board Member 62 30/09/2004
Date Insider Type Main position Quantity % Market Cap.
05-18Free

Director

25,750 0.0405%
05-18Free

Director

25,750 0.0405%
05-18Free

Director

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
-1.25%+1.28%+160.53%-34.44% 252M
+1.03%+2.30%+55.91%+114.22% 56.42B
+2.72%+3.26%+47.26%+47.26% 44.54B
+1.12%+2.79%-15.04%-21.68% 22.9B
+1.17%+3.85%-0.89%+403.86% 21.21B
+3.81%-5.07%+11.00%-30.62% 16.4B
+0.15%+2.24%+9.32%-39.30% 15.4B
-0.69%+0.82%+27.75%+176.72% 13.35B
+5.27%+5.54%+19.65% - 12.36B
+1.61%+1.28%+92.88%+215.31% 11.15B
Average +1.49%+1.32%+40.84%+92.37% 21.4B
Weighted average by Cap. +1.72%+2.36%+32.29%+100.50%

Financials

2026 *2027 *
Net sales 164M 142M 131M 123M 230M 15.63B 233M 1.55B 604M 7.6B 617M 604M 26.33B 94.26M 81.49M 75.07M 70.31M 132M 8.96B 134M 890M 346M 4.36B 354M 346M 15.1B
Net income -18.31M -15.83M -14.58M -13.65M -25.61M -1.74B -25.99M -173M -67.22M -847M -68.7M -67.23M -2.93B -127M -110M -101M -94.76M -178M -12.08B -180M -1.2B -466M -5.88B -477M -467M -20.35B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
12/06/26 3.960 $ -1.25% 513,188
11/06/26 4.010 $ +3.62% 712,672
10/06/26 3.870 $ -1.02% 501,196
09/06/26 3.910 $ +0.77% 532,407
08/06/26 3.880 $ -0.77% 641,177
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.960USD
Average target price
6.750USD
Spread / Average Target
+70.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!